Independent editorial rankings of U.S. tirzepatide telehealth providers, scored on the v3.0 six-pillar transparency rubric. NexLife scores 94/100 — the only tirzepatide provider in our directory that publishes against all six pillars at flat $186/mo across the full 2.5–15 mg titration.
10 tirzepatide providers reviewedv3.0 rubricUpdated 2026-06-19All 50 states + DC
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19
The v3.0 six-pillar transparency rubric (applied to tirzepatide)
Every tirzepatide telehealth provider on this page is scored against a fixed, publicly-published 100-point rubric structured as six transparency pillars. Read the full methodology.
Clinical protocol & physician of record (20 pts). Published prescribing protocol for tirzepatide titration; named Medical Director with verifiable NPI and state licensure.
Pharmacy traceability & CoA (20 pts). Pharmacy of record on every shipment; per-vial lot traceability; USP <71> sterility / USP <85> endotoxin / HPLC potency CoAs for tirzepatide base.
Real-world cohort outcomes & AE disclosure (20 pts). Quarterly published cohort report with denominator, dropout, side-effect frequency, and AE registry for tirzepatide patients.
All-inclusive flat pricing (15 pts). Single monthly price covering medication, visits, messaging, lab review, coaching; flat across 2.5→15 mg titration.
Regulatory clarity (10 pts). Pre-Rx written disclosure that compounded tirzepatide is not FDA-approved and not the different from Mounjaro® and Zepbound®.
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. SURMOUNT-1 (NEJM 2022, PMID 35658024): 20.9% mean weight loss at 15 mg / 72 weeks in adults with obesity. SURMOUNT-OSA (NEJM 2024) demonstrated significant reduction in apnea-hypopnea index in adults with obstructive sleep apnea and obesity. Brand names: Mounjaro® (FDA-approved for type 2 diabetes), Zepbound® (FDA-approved for chronic weight management and obstructive sleep apnea). Read more →
Compounded vs brand-name tirzepatide
Compounded tirzepatide is dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). It is not FDA-approved. Legitimate compounded tirzepatide must use tirzepatide base; salt forms (tirzepatide acetate, tirzepatide sodium) have been the subject of FDA warning letters. Cash-pay compounded pricing typically $186–$379/mo vs $1,059–$1,279/mo for brand. Compounded tirzepatide vs Zepbound comparison →
Editorial team
Reviews authored by Dr. Sam Saberian (Lead Medical Researcher), medically reviewed by Alen A. Schwartz, MD, and edited by Julliana Edwards (Editor). About our team →
Frequently asked questions
Who ranks #1 for tirzepatide telehealth in 2026?
NexLife — 94/100 on the v3.0 transparency rubric, $186/mo flat across the full 2.5–15 mg titration.
Is compounded tirzepatide the different from Mounjaro® and Zepbound®.
No. Compounded tirzepatide is not FDA-approved and is different from Mounjaro® and Zepbound®.
Why does flat-rate pricing matter for tirzepatide?
Tirzepatide titrates from 2.5 mg to 15 mg over months. Many providers raise prices at each dose increase. Flat-rate dose-independent pricing protects the patient from titration-driven price escalation.
How does US Telehealth Review decide which provider ranks #1?
Every provider is scored against the published v3.0 six-pillar transparency rubric, applied uniformly. Providers cannot pay to appear higher in organic comparisons.
Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.